Abstract: The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.
Type:
Grant
Filed:
November 28, 2011
Date of Patent:
January 22, 2013
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Inventors:
Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann
Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.
Type:
Grant
Filed:
February 10, 2012
Date of Patent:
January 8, 2013
Assignees:
Nektar Therapeutics, Baxter International Inc., Baxter Healthcare S.A.
Inventors:
Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
Abstract: Suitable dyes are used herein to indicate the presence of microbial contamination by spraying them onto surfaces in the form of an aqueous solution. The dye solution may also be allowed to dry, thus producing the dried residue of an aqueous solution. It's believed that these dyes change color in response to a change in polarity of the environment. Since water is a polar solvent and most bacteria are made from non-polar substances, the presence of bacteria changes the polarity of the environment, triggering a change visible by the unaided eye.
Type:
Grant
Filed:
March 30, 2010
Date of Patent:
December 25, 2012
Assignee:
Kimberly-Clark Worldwide, Inc.
Inventors:
Jason Lye, John Gavin MacDonald, Ning Wei, Stephanie M. Martin
Abstract: Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-l-lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-l-lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PR11, PR39, VEGF, bFGF, a polyarginine/DNA plasmid complex, or a DNA/polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors.
Abstract: The present invention relates to methods for enhancing the hemodynamic stability of an individual undergoing surgery by administering a composition comprising a hemoglobin-based oxygen carrier. In one embodiment, the present invention relates to the use of polyalkylene oxide modified hemoglobins with reduced cooperativity and a high oxygen affinity to enhance oxygen offloading as a preventative measure to avoid hemodynamic stability-related complications during surgery.
Abstract: The present invention relates to a method for production of a diol form represented by the formula (2), which includes filtering a culture fluid obtained by microbial conversion using a compound represented by the following formula (1a) and/or formula (1b) as a substrate, using a filter having an aperture size of 10 to 100 ?m; washing the residue on the filter with water or a solvent having an SP value outside the range of 8.3 to 20 (cal/cm3)1/2; subsequently dissolving the obtained cake in a solvent having an SP value of 8.3 to 20 (cal/cm3)1/2; and then filtering or centrifuging the solution. According to the present invention, 1-(2-hydroxyethyl)-2,5,5,8a-tetramethyldecahydronaphthalen-2-ol, which is useful as an intermediate for the production of 3a,6,6,9a-tetramethyldodecahydronaphtho[2,1-b]furan, can be efficiently produced at high purity.
Abstract: The present disclosure provides charged lipoprotein complexes that include as one component a negatively charged phospholipid that is expected to impart the complexes with improved therapeutic properties.
Abstract: Methods and compositions for treating post-myocardial infarction damage are herein disclosed. In some embodiments, a carrier with a treatment agent may be fabricated. The carrier can be formulated from a bioerodable, sustained-release substance. The resultant loaded carrier may then be suspended in at least one component of a two-component matrix system for simultaneous delivery to a post-myocardial infarction treatment area.
Type:
Grant
Filed:
June 5, 2006
Date of Patent:
May 29, 2012
Assignee:
Advanced Cardiovascular Systems, Inc.
Inventors:
Eugene Michal, Shubhayu Basu, Hai-Chien Kuo
Abstract: A standardized, lyophilized edible food containing a biologically safe stable marker for use in the measurement of gastric emptying by the quantification of marker excreted in the breath of the patient.
Type:
Grant
Filed:
May 15, 2008
Date of Patent:
May 15, 2012
Assignee:
Advanced Breath Diagnostics, LLC
Inventors:
Kerry C. Bush, Keith D. Evans, Stanley J. Konopka
Abstract: The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present invention.
Type:
Grant
Filed:
November 7, 2008
Date of Patent:
May 8, 2012
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Abstract: The present invention relates to a proteinaceous construct comprising a blood coagulation factor, e.g., Factor VIII (FVIII), being bound to at least one water soluble polymer, including a poly(alkylene oxide) such as polyethylene glycol (PEG). Further the present invention relates to methods of preparing PEGylated blood coagulation factor, e.g., FVIII, in the presence of bound antibodies. The invention also relates to methods for prolonging the in vivo-half-life of blood coagulation factor, e.g., FVIII, in the blood of a mammal having a bleeding disorder associated with functional defects or deficiencies of blood coagulation factor, e.g., FVIII.
Type:
Grant
Filed:
October 14, 2009
Date of Patent:
March 27, 2012
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Inventors:
Artur Mitterer, Michael Graninger, Meinhard Hasslacher
Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.
Type:
Grant
Filed:
December 27, 2007
Date of Patent:
March 13, 2012
Assignees:
Nektar Therapeutics, Baxter International Inc., Baxter Healthcare S.A.
Inventors:
Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
Abstract: The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.
Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
Type:
Grant
Filed:
January 20, 2011
Date of Patent:
December 6, 2011
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
Type:
Grant
Filed:
January 20, 2011
Date of Patent:
December 6, 2011
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
Type:
Grant
Filed:
January 20, 2011
Date of Patent:
December 6, 2011
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
Type:
Grant
Filed:
January 20, 2011
Date of Patent:
December 6, 2011
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
Type:
Grant
Filed:
January 20, 2011
Date of Patent:
December 6, 2011
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
Type:
Grant
Filed:
January 20, 2011
Date of Patent:
November 29, 2011
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule having at least a portion of the B domain intact, which is conjugated to a water-soluble polymer such as polyethylene glycol having a molecular weight of greater than 10,000 Daltons. The construct has a biological activity of at least 80% of the biological activity of native Factor VIII, and the in vivo half-life of the construct is increased by at least 1.5 fold as compared to the in vivo half-life of native factor FVIII.
Type:
Grant
Filed:
March 8, 2010
Date of Patent:
November 8, 2011
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Inventors:
Juergen Siekmann, Katalin Varadi, Herbert Gritsch, Peter Turecek